Quiz|Articles|July 12, 2026

Dermatology Times Spot Test: July 12, 2026

Author(s)Marie Bosslett, Assistant Editor

Listen

0:00 / 0:00

Key Takeaways

A recurring quiz series is framed as a weekly mechanism to evaluate and reinforce dermatology knowledge across foundational concepts and new developments.
This week’s clinical-news focus centers on Evommune updates relevant to chronic spontaneous urticaria.
Reader-generated quiz questions are solicited to broaden participation and diversify future content.
Submissions are directed to editor Marie Bosslett through a provided professional email contact.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Welcome to Dermatology Times' Spot Test!

Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on the latest news from Evommune in chronic spontaneous urticaria.

Do you have a set of quiz questions to share? Contact editor Marie Bosslett at [email protected] to contribute.

What was the primary outcome of Evommune's phase 2b trial of EVO756 in CSU?

Which mechanism of action best describes EVO756?

Approximately how many patients were enrolled in this phase 2b trial?